1. Introduction: Has Neuronox Been Directly Compared With BOTOX?

Neuronox is a botulinum toxin type A (BoNT-A) product manufactured by Medytox Inc., Republic of Korea. Published randomized clinical trials have directly compared the Neuronox preparation with BOTOX (onabotulinumtoxinA) in both aesthetic and therapeutic settings. ［1–5］

The evidence includes four clinical areas:

• Moderate-to-severe glabellar lines

• Essential blepharospasm

• Spastic equinus in children with cerebral palsy

• Post-stroke upper-limb spasticity

These studies are important because they provide direct active-comparator evidence rather than relying exclusively on separate trials of different products.

The central finding across the identified comparative programs is that Neuronox met the prespecified non-inferiority criteria for the relevant study endpoints. However, each finding applies to its own population, treatment protocol and assessment method. ［1–4］

Non-inferiority does not establish universal interchangeability, superiority or an unrestricted 1:1 dose-conversion rule.

This article reviews the four comparative programs and explains what their findings support in clinical practice.

2. Overview of the Direct Comparative Evidence

The Neuronox clinical evidence base extends beyond aesthetic indications. Randomized trials have evaluated the product against onabotulinumtoxinA in different clinical populations and treatment settings.

Table 1. Direct Comparative Trials of Neuronox and BOTOX

Clinical Setting

Study Design

Products Compared

Main Comparative Finding

Glabellar lines

Randomized, double-blind, active-controlled Phase III

Neuronox preparation vs onabotulinumtoxinA

Prespecified non-inferiority criterion met

Essential blepharospasm

Randomized, double-blind comparative trial

Meditoxin/Neuronox vs BOTOX

Primary non-inferiority criterion met

Cerebral-palsy spastic equinus

Multicentre, randomized, double-blind trial

Neuronox vs BOTOX

Primary non-inferiority criterion met

Post-stroke upper-limb spasticity

Multicenter, randomized, double-blind Phase III

Neuronox vs BOTOX

Comparative assessment used a prespecified non-inferiority framework

The studies collectively demonstrate that Neuronox has been investigated in direct randomized comparisons across multiple clinical indications. ［1–4］

Nevertheless, outcomes from different indications should not be combined into a single efficacy estimate. Each study addresses a distinct clinical question.

3. Glabellar Lines: Randomized Phase III Evidence

The aesthetic comparative study evaluated a Neuronox preparation against onabotulinumtoxinA in participants with glabellar lines.

The trial was randomized, double-blind, active-controlled and multicenter, with 314 participants. Its primary comparative assessment included responder rates at Week 4. ［1］

3.1 What Were the Reported Results?

The study reported the following Week-4 responder rates:

Table 2. Glabellar-Line Phase III Trial: Week-4 Results

Study Parameter

Neuronox Preparation

OnabotulinumtoxinA (BOTOX)

Total Study Population

314 participants (both groups combined)

314 participants (both groups combined)

Week-4 Responder Rate

93.7%

94.5%

Comparative Conclusion

Prespecified non-inferiority criterion met

Active comparator

The trial met its prespecified non-inferiority criterion. ［1］

The responder rates describe the outcomes observed at the specified assessment time. They should not be interpreted as evidence that every patient will experience the same response.

3.2 What Does the Finding Support?

This trial provides direct comparative evidence for the Neuronox preparation in the studied glabellar-line population.

It supports a non-inferiority conclusion for the defined study endpoint, under the treatment and assessment conditions specified in the protocol.

It does not establish that the two products have identical formulations, identical effects across all facial regions, or universally interchangeable potency units.

3.3 Why Is This Study Relevant to Neuronox?

Unlike an indirect comparison assembled from separate publications, this trial evaluated the Neuronox preparation and an onabotulinumtoxinA comparator within the same randomized protocol.

That design allows a more direct interpretation of the observed treatment difference for the studied endpoint.

The study therefore forms an important part of the product-specific clinical evidence supporting Neuronox in aesthetic medicine.

4. Essential Blepharospasm: Direct Comparative Evidence

Essential blepharospasm is a neurological condition characterized by involuntary contractions of the muscles around the eyes.

A randomized, double-blind comparative trial evaluated Meditoxin against Botox in patients with essential blepharospasm. The publication identifies Meditoxin as another name for Neuronox. ［2］

The study reported that its primary non-inferiority criterion was met in the enrolled population.

4.1 What Does This Study Add?

The blepharospasm trial provides evidence for Neuronox in a therapeutic setting distinct from cosmetic treatment.

It demonstrates that the product has been evaluated against an active onabotulinumtoxinA comparator for a neurological indication.

However, the endpoint and treatment context differ from those of a glabellar-line study.

The therapeutic result should therefore not be used as an independent claim about cosmetic efficacy.

5. Cerebral-Palsy Spastic Equinus: Pediatric Comparative Evidence

Spastic equinus is a movement-related problem that may occur in children with cerebral palsy. Increased muscle activity can affect ankle position and walking.

A multicentre, randomized, double-blind trial compared Neuronox with BOTOX in children with cerebral-palsy spastic equinus. ［3］

The study met its prespecified primary non-inferiority criterion.

5.1 Why Is This Evidence Important?

This trial extends the direct comparative evidence for Neuronox into a pediatric therapeutic population.

It provides information about the studied treatment regimen and outcomes in children with cerebral palsy.

However, pediatric therapeutic findings cannot be automatically generalized to adult aesthetic indications.

Differences in the patient population, target muscles, dose, treatment goals and outcome measures must be considered.

6. Post-Stroke Upper-Limb Spasticity: Phase III Evidence

Post-stroke upper-limb spasticity can involve increased muscle tone and resistance to passive movement in the affected arm.

A multicenter, randomized, double-blind Phase III trial compared Neuronox with BOTOX in patients with post-stroke upper-limb spasticity. ［4］

The study used change in the Modified Ashworth Scale (MAS) as its primary outcome and employed a prespecified non-inferiority framework.

6.1 What Is the Modified Ashworth Scale?

The Modified Ashworth Scale is a clinical assessment of resistance encountered during passive movement.

In a spasticity trial, a change in MAS can provide information about the treatment's effect on the assessed muscle tone.

However, MAS is not the same as a direct measure of functional independence, patient satisfaction or improvement in every daily activity.

The study's conclusions should remain tied to the primary outcome and additional measures actually evaluated.

6.2 What Does This Trial Contribute?

The post-stroke trial adds another direct comparative program to the Neuronox evidence base.

Together with the blepharospasm and cerebral-palsy studies, it demonstrates that Neuronox has been investigated in multiple therapeutic settings rather than exclusively in aesthetic medicine.

7. What Do the Four Comparative Programs Establish?

The four identified programs provide product-specific randomized evidence involving Neuronox and an onabotulinumtoxinA comparator. ［1–4］

They support conclusions about the studied indications, populations, doses and endpoints.

They do not establish that every outcome is identical between products.

Table 3. Supported Findings and Interpretation Limits

Evidence

What the Findings Support

What They Do Not Establish

Glabellar-line Phase III

Study-specific non-inferiority for the defined aesthetic endpoint

Superiority or identical outcomes in every facial region

Blepharospasm trial

Direct comparative therapeutic evidence

Cosmetic efficacy in an unstudied population

Cerebral-palsy trial

Direct comparative pediatric therapeutic evidence

Applicability to every pediatric or adult indication

Post-stroke Phase III

Comparative evidence using the specified spasticity endpoint

Identical functional outcomes across all measures

Combined evidence base

Neuronox has been directly studied against BOTOX in multiple settings

Universal interchangeability or a global dose-conversion rule

A responsible summary should distinguish between the breadth of a product's clinical research program and the specific conclusions supported by individual trials.

8. Does Non-Inferiority Mean Neuronox and BOTOX Are Identical?

No.

A non-inferiority trial is designed to evaluate whether the difference between treatments remains within a prespecified margin for a defined endpoint.

The interpretation depends on the study protocol, statistical analysis, treatment regimens and population.

Non-inferiority does not independently establish:

• Identical product formulations or manufacturing processes

• Equivalent outcomes for every indication

• Identical safety profiles in all populations

• Universal interchangeability of potency units

• Superiority of one product over the other

The clinical findings are meaningful precisely because they were obtained under controlled comparative conditions. They should be communicated without extending their conclusions beyond those conditions.

9. Can Neuronox and BOTOX Units Be Converted 1:1?

A numerical dose relationship used in a comparative trial should not be treated as a universal conversion rule.

Botulinum toxin potency units are product-specific. The dose selected in a study is part of its treatment protocol.

Even when a study compares equal numerical units, that design does not establish interchangeability across all indications, injection patterns or patient populations.

Clinical dosing must be assessed against the current approved product information for the relevant jurisdiction.

10. What About Comparative Safety?

The randomized trials provide safety information for the studied Neuronox and comparator regimens.

However, a non-inferiority finding for an efficacy endpoint does not automatically establish equivalent safety.

Safety interpretation requires examination of the original publications, including adverse-event definitions, event frequencies, severity, treatment exposure, sample size and follow-up.

The source summary used for this article does not provide complete study-level adverse-event rates for all four programs. Accordingly, a numerical comparative safety table cannot be presented without further verification.

The current locally approved product information should also be consulted for contraindications, warnings and administration requirements.

11. How Should Neuronox Be Presented in Evidence-Based Communication?

Neuronox can be described as a BoNT-A product with published direct randomized comparative evidence against onabotulinumtoxinA across aesthetic and selected therapeutic indications.

For glabellar lines, the identified Phase III study reported Week-4 responder rates of 93.7% for the Neuronox preparation and 94.5% for onabotulinumtoxinA, meeting the prespecified non-inferiority criterion. ［1］

This is a product-specific, evidence-supported finding.

However, communications should not convert it into a claim of universal superiority or unrestricted interchangeability.

Table 4. Evidence-Based Communication Checklist

Communication Topic

Recommended Information to Include

Product identity

Neuronox and the exact preparation evaluated

Comparator

BOTOX/onabotulinumtoxinA

Indication

Glabellar lines or the specific therapeutic condition

Study design

Randomized, double-blind and active-controlled, where applicable

Efficacy result

Exact endpoint, assessment time and verified result

Statistical conclusion

Non-inferiority when that was the prespecified finding

Safety

Verified study-level results and current product information

Dose

Protocol-specific regimen; no universal conversion claim

12. Frequently Asked Questions

Has Neuronox been directly compared with BOTOX?

Yes. Published randomized trials have evaluated Neuronox or the Meditoxin preparation identified with Neuronox against BOTOX/onabotulinumtoxinA in glabellar lines and selected therapeutic indications. ［1–4］

What did the glabellar-line Phase III trial report?

The study included 314 participants and reported Week-4 responder rates of 93.7% for the Neuronox preparation and 94.5% for onabotulinumtoxinA. The prespecified non-inferiority criterion was met. ［1］

Does the evidence include therapeutic indications?

Yes. The identified programs include essential blepharospasm, cerebral-palsy spastic equinus and post-stroke upper-limb spasticity. ［2–4］

Can therapeutic trial results be used to claim cosmetic efficacy?

No. Each trial's findings apply to its studied population, indication and endpoints.

Do the trials establish that Neuronox is superior to BOTOX?

No. The identified comparative conclusions are based on study-specific non-inferiority assessments, not universal superiority.

Can the products be substituted using a universal 1:1 unit ratio?

No universal conversion or interchangeability rule should be inferred from these studies. Dosing must follow the relevant product-specific information.

13. Conclusion

Neuronox has a published direct comparative clinical evidence base involving BOTOX/onabotulinumtoxinA across four identified clinical settings: glabellar lines, essential blepharospasm, cerebral-palsy spastic equinus and post-stroke upper-limb spasticity. ［1–4］

The glabellar-line Phase III study included 314 participants and reported Week-4 responder rates of 93.7% and 94.5% for the Neuronox preparation and onabotulinumtoxinA, respectively, meeting its prespecified non-inferiority criterion. ［1］

The therapeutic studies add evidence in distinct patient populations and treatment settings.

Together, these programs demonstrate that Neuronox has been evaluated through direct randomized comparisons in both aesthetic and therapeutic medicine. Their findings should be interpreted according to the exact products, indications, doses, endpoints and populations studied.

References

［1］ Lee WS, et al. Efficacy and safety of a new botulinum toxin type A for glabellar lines: randomized, double-blind, active-controlled, multicenter phase III study. Dermatol Surg. 2013;39:171–178. doi:10.1111/dsu.12072.

［2］ Yoon JS, Kim JC, Lee SY. Meditoxin versus Botox in essential blepharospasm. Korean J Ophthalmol. 2009;23:137–141. doi:10.3341/kjo.2009.23.3.137.

［3］ Kim K, et al. Neuronox versus BOTOX for spastic equinus gait in children with cerebral palsy. Dev Med Child Neurol. 2011;53:239–244. doi:10.1111/j.1469-8749.2010.03830.x.

［4］ Nam HS, et al. Neuronox versus BOTOX for post-stroke upper-limb spasticity. PLoS ONE. 2015;10:e0128633. doi:10.1371/journal.pone.0128633.

［5］ NEURONOX (Botulinum Toxin Type A). Thai product information. Revised April 3, 2023. Manufacturer: Medytox Inc., Republic of Korea.

• COMPLETE SITE INDEX

BotoxWiki provides evidence-focused educational content with transparent sourcing and editorial standards.

Clinical & Anatomy

Evidence & Review

Editorial & Trust

Reference Standard

BotoxWiki provides evidence-based content, medical review, and a neutral editorial approach to botulinum toxin formulations and anatomical guidance.

© BotoxWiki Clinical Reference Directory.